N/A N=116 Coping Skills Treatment for Smoking Cessation
Nicotine Dependence
Primary: Number of Participants With Biochemically Verified Smoking Abstinence — 11; 12 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=12 Evaluate Whether Combination Therapy With Methotrexate and Raptiva in Psoriasis Patients is Safe and Increases Efficacy
Psoriasis
Primary: PASI -- Psoriasis Area and Severity Index
Phase 2 N=25 Dose-finding Study of New Tolvaptan Formulation in Subjects With ADPKD
Autosomal Dominant Polycystic Kidney Disease
Primary: Maximum (Peak) Plasma Concentration of the Drug [Cmax] and Minimum (Trough) Plasma Concentration of the Drug [Cmin] After Tolvaptan Treatment on Day 7. — 140; 175; 350…
Phase 2 N=30 Administration of GRASPA (Suspension of Erythrocytes Encapsulating L-asparaginase) in Elderly Patients With First Line Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia
Primary: Efficacy Primary Endpoint - Percentage of Patients Responding to Treatment — 0; 11; 10 Participants
N/A N=14 Evaluating the Methylphenidate Patch to Treat Former Stimulant Users With ADHD
Adult Attention Deficit Hyperactivity Disorder (ADHD)
Primary: ADHD Symptom Severity — -17.93 units on a scale
Phase 2 N=129 A Comparison of Ketamine Infusion Versus Placebo in Opioid Tolerant and Opioid Naive Patients After Spinal Fusion
Spinal Fusion
Primary: Hydromorphone Use/24 Hours postOP in mg/kg — .13; .09; .27; .19 mg/kg
Phase 4 N=65 Liposomal Bupivacaine for Post Operative Pain After Knee Replacement Surgery
Post-operative Pain
Primary: Pain Intensity at Movement — 8.95; 7.91 VAS Scale
Phase 2 N=1,768 Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Alzheimer Disease · Mild Cognitive Impairment · Neurodegenerative Diseases
Primary: Number of Participants Experiencing Treatment-emergent Adverse Events Considered Related to Florbetapir Administration — 21; 6; 5; 5 Participants
Phase 3 N=6,198 Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES)
Cardiovascular Disease
Primary: Percentage of Participants With Primary Major Adverse Cardiovascular Events (MACE) Composite (75% Interim Analysis) — 8.0; 8.0 percentage of participants
N/A N=30 Pilot Evaluation Comparing Regional Distribution of Ventilation During Lung Expansion Therapy
Ventilation · Breathing · Atelectasis
Primary: Regional Distribution of Ventilation — -4.9; -5.6 percentage of dorsal redistribution — p=.90
Phase 4 N=13 Effects of N-acetylcysteine on Cardiorespiratory Control in COPD Patients With Mild-to-moderate Airflow Obstruction
Pulmonary Disease, Chronic Obstructive
Primary: Plasma Redox Status - Circulating Glutathione — 8.97; 7.05 micromolar
N/A N=91 fMRI Study of Treatment Changes in Major Depression
Major Depression · Treatment
Primary: Blood Oxygen-level Dependent Activations During an Emotional Distractor Task Between fMRI Scans of Depressed Participants in the CBT Group and Control Participants…
Phase 3 N=306 Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism
Male Hypogonadism
Primary: Serum Testosterone Cavg — 76; 43; 61 Participants
Phase 2 N=129 Safety and Pharmacokinetics Study of Anthrax Immune Globulin Intravenous (AIGIV)
Anthrax
Primary: Number of Participants Reporting Adverse Events (AEs) — 28; 5; 29; 11 Participants
Phase 4 N=89 Safety and Tolerability Study of Pirfenidone in Combination With Nintedanib in Participants With Idiopathic Pulmonary Fibrosis (IPF)
Idiopathic Pulmonary Fibrosis
Primary: Percentage of Participants Who Complete 24 Weeks of Combination Treatment on Pirfenidone at a Dose of 1602-2403 mg/Day and Nintedanib at a Dose of 200-300 mg/Day — 77.5…